Data does not support nod for BioMarin's DMD drug: FDA staff
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Concerns on Drisapersen Positive for Sarepta's (SRPT) Eteplirsen - Needham & Company
November 20, 2015 11:19 AM ESTNeedham & Company analyst Chad Messer said FDA concerns on BioMarin's drisapersen should be a positive for Sarepta Therapeutic (NASDAQ: SRPT) Eteplirse. The firm reiterated a Buy rating and price target of $55.
Messer commented, "The FDA released briefing documents for BioMarin's drisapersen this... More
Despite Harsh BioMarin (BMRN) Briefing Docs, the Jury is Still Out - Leerink Partners
November 20, 2015 10:21 AM ESTLeerink Partners analyst Joseph Schwartz weighed in on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) following today's FDA briefing docs, noting they were even more harsh then expected. That said, the analyst said the jury is still out.
Schwartz commented, "FDA briefing documents for... More
BioMarin Pharma (BMRN) Briefing Docs 'Ugly' - Baird (SRPT)
November 20, 2015 9:50 AM ESTBaird analyst Brian Skorney weighed in on BioMarin Pharma (NASDAQ: BMRN) after today's Drisapersen briefing docs, calling them "ugly"
Skorney commented, "The FDA isn't even offering voting questions to the panelist and the review on risk benefit states: The benefit of drisapersen in exon... More
